Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient’s CD8+ “killer” T-cells against cancer. Heat’s T-cell Activation Platform (TCAP) produces therapies designed to turn cold” tumors “hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness.Product candidates are produced from allogeneic cell lines composed of tumor proteins common among all cancers. The immunotherapies combine a T-cell activator and a T-cell co-stimulator into a single drug, eliminating the need for multiple, independent biologic treatments.

Bank Name Heat Biologics, Inc.
Stock Exchange NASDAQ
Symbol HTBX
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman Mr. Jeffrey Alan Wolf
CEO Mr. Jeffrey Alan Wolf
Employees 19
Website www.heatbio.com
Registered Year 2008

UpdateContent
UpdateContent
UpdateContent